Phase 3 study of Exparel for postoperative analgesia

Pacira Pharmaceuticals announced new data from its Phase 3 study to evaluate the efficacy and safety of the intraoperative administration of Exparel (bupivacaine extended-release liposome injection) for prolonged postoperative analgesia in subjects undergoing first metatarsal osteotomy (bunionectomy). Study results from this multicenter, randomized, double-blind, parallel-group, placebo-controlled bunionectomy trial demonstrate that the median time to first use of opioid rescue medication was 7.2 hours for patients treated with Exparel compared with 4.3 hours for patients treated with placebo (p<0.0001).  The trial studied 193 patients at four separate clinical study sites in the U.S.

Exparel is a novel long-acting, sustained-release analgesic formulation of bupivacaine HCl being developed for prolonged postoperative analgesia.

For more information call (973) 254 3560 or visit www.pacira.com